top of page
VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
​
​
Aiming to submit NDA in 2020-2021.
VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
​
​
Aiming to submit NDA in 2020-2021.
VTS-K: Ketamine + VTS Aspirin for Postoperative Pain
VTS-K: Ketamine + VTS Aspirin for Postoperative Pain
Media
Tuesday, January 12th, 2021 8:00 am ET
Tuesday, September 1st, 2020 8:00 am ET
Tuesday, January 7th, 2020 8:00 am ET
Tuesday, October 22nd, 2019 8:00 am ET
bottom of page